Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Intensity Therapeutics updates Q2 2026 results; INVINCIBLE programs advance

Aug 11, 2026, 7:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive clinical signals (71% vs 42% pCR) and progress on INVINCIBLE-3 restart plus EU site activity could support a near-term rebound, though dilution risk from ATM funding remains a constraint.

AI summary

What happened, with direct paths to the underlying reporting

Intensity Therapeutics reports Q2 2026 results and updates on INVINCIBLE-3 restart and INVINCIBLE-4 progress. The company notes a tighter cash runway with an ATM facility and ongoing partnership discussions, signaling near-term catalysts but continued funding risk, including EU site activity and potential collaborations.

INTS plans limited US INVINCIBLE-3 enrollment by Q3 2026.
INVINCIBLE-4: 71% pCR in Cohort A vs 42% SOC in 14 patients.
Cash equals $9.5M as of 6/30/2026; ATM facility up to $60M.
ATM net proceeds: $1.6M in Q2 2026; $1.3M post-quarter.
Management cites partnerships and EU site progress; BIO discussions ongoing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Intensity Therapeutics updates Q2 2026 results; INVINCIBLE programs advance

Promising Early Data from INVINCIBLE-4 Study Could Boost INT230-6's Outlook